The Phase II/III study of Moderna’s Covid-19 vaccine, mRNA-1273, among adolesecents has met its primary immunogenicity endpoint. Using the primary definition, no Covid-19 cases were identified among the participants who had received two doses of the vaccine. The TeenCOVE study was carried out among 3,700 participants aged between 12 and 18 years in the US. The vaccine demonstrated 93% efficacy in seronegative individuals 14 days after the first dose.

Pharmaceutical company MSN Laboratories is commencing a Phase III clinical trial of molnupiravir capsules for treating Covid-19 in India. The company confirmed that it had sought approval from the Drug Controller General of India to conduct a safety and efficacy study of the drug to treat mild to moderate symptoms in Covid-19 patients. The clinical trials are expected to take place at more than 40 sites across the country, enrolling more than 2,400 individuals with mild to moderate symptoms.

Clinical-stage biopharmaceutical company Xencor has entered into a technology licensing agreement with Bristol Myers Squibb to provide the latter access to its Xtend Fc technology to extend the half-life of a novel antibody combination therapy that neutralises the SARS-CoV-2 virus. The Phase I clinical study to examine dosing and safety of the therapy is being conducted at Rockefeller University Hospital, while the initial Phase II and III studies will form a part of the NIH ACTIV-2 trial investigating treatments for Covid-19 outpatients.